We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+22.77%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.2B
AUM Growth
+$2.02B
Cap. Flow
+$1.08B
Cap. Flow %
8.87%
Top 10 Hldgs %
86.71%
Holding
137
New
4
Increased
21
Reduced
9
Closed
18

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.35B
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$11.4M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$9.33M
4
ASND icon
Ascendis Pharma A/S
ASND
+$8.29M
5
NGNE icon
Neurogene
NGNE
+$6.99M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$106M
2
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$19.5M
3
ARRY
Array Biopharma Inc
ARRY
+$10.6M
4
EXEL icon
Exelixis
EXEL
+$8.13M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 98.27%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIXC
101
AIxCrypto Holdings Inc
AIXC
$22.7M
$568K ﹤0.01%
3
– –
ADAP
102
DELISTED
Adaptimmune Therapeutics
ADAP
$551K ﹤0.01%
100,000
– –
TARA icon
103
Protara Therapeutics
TARA
$228M
$523K ﹤0.01%
7,465
-2,270
-23% -$170K
BIVV
104
DELISTED
Bioverativ Inc. Common Stock
BIVV
$449K ﹤0.01%
+8,249
New +$406K
DVAX
105
DELISTED
Dynavax Technologies
DVAX
$446K ﹤0.01%
75,000
– –
BDSI
106
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$399K ﹤0.01%
210,021
– –
CCXI
107
DELISTED
ChemoCentryx, Inc.
CCXI
$357K ﹤0.01%
49,064
– –
WINT
108
DELISTED
Windtree Therapeutics Inc
WINT
$291K ﹤0.01%
254,973
– –
TMBR
109
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$191K ﹤0.01%
+25
New +$173K
BGMSP
110
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$83K ﹤0.01%
13,253
– –
BTX.WS
111
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$12K ﹤0.01%
20,084
– –
ABBV icon
112
AbbVie
ABBV
$468B
– –
-1,685,994
Closed -$106M
ALDX icon
113
Aldeyra Therapeutics
ALDX
$91.7M
– –
-142,000
Closed -$760K
ALNY icon
114
Alnylam Pharmaceuticals
ALNY
$31.6B
– –
-11,340
Closed -$425K
ARCT icon
115
Arcturus Therapeutics
ARCT
$382M
– –
-333,766
Closed -$4.91M
ENTA icon
116
Enanta Pharmaceuticals
ENTA
$392M
– –
-75,357
Closed -$2.52M
IONS icon
117
Ionis Pharmaceuticals
IONS
$9.93B
– –
-57,140
Closed -$2.73M
NERV icon
118
Minerva Neurosciences
NERV
$231M
– –
-32,351
Closed -$3.04M
PRQR icon
119
ProQR Therapeutics
PRQR
$330M
– –
-212,698
Closed -$1.04M
QURE icon
120
uniQure
QURE
$3.36B
– –
-230,000
Closed -$1.29M
SCYX icon
121
SCYNEXIS
SCYX
$50.7M
– –
-5,845
Closed -$1.49M
TENX icon
122
Tenax Therapeutics
TENX
$65.5M
– –
-13
Closed -$819K
APTO
123
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-574
Closed -$359K
CNCE
124
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-152,964
Closed -$1.57M
SRRA
125
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-5,000
Closed -$298K
2 3 4
5
6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2017 Portfolio in Review

As of Q1 2017, Julian Baker held 137 positions worth $12.2B, up 20% from $10.2B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Julian Baker deployed $1.08B of net new capital in Q1 2017, opening 4 new positions and adding to 21 existing holdings. Its largest new stake was AnaptysBio: 150,000 shares worth $4.16M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 88% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $10.6M trimmed.

  • Julian Baker's largest Q1 2017 buy was AnaptysBio: 150,000 shares worth $4.16M.
  • Julian Baker added most to Incyte in Q1 2017, an estimated $1.35B increase.
  • Julian Baker's biggest Q1 2017 reduction was Array Biopharma Inc, cutting an estimated $10.6M.
  • Julian Baker fully exited AbbVie in Q1 2017, selling an estimated $106M.
  • Julian Baker's ten largest holdings make up 87% of its $12.2B portfolio in Q1 2017.
  • Julian Baker opened 4 new positions and closed 18 in Q1 2017.
  • Julian Baker's portfolio value rose 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.